Clinical Report: Trends Over Time in HbA1c Levels in Pediatric and Adolescent Patients with Type 1 Diabetes
Overview
This study evaluates the trends in HbA1c levels among pediatric and adolescent patients with type 1 diabetes (T1D) over 23 years, revealing a significant decline in HbA1c levels and variations based on sociodemographic factors. The findings underscore the impact of advancements in diabetes management on glycemic control in this population.
Background
Type 1 diabetes (T1D) is associated with serious long-term complications, making effective glycemic control crucial for improving patient outcomes. The management of T1D has evolved significantly, particularly in Taiwan, with advancements in technology and healthcare policies. Understanding trends in HbA1c levels is essential for assessing the effectiveness of these interventions and guiding future clinical practices.
Data Highlights
Year
Mean HbA1c (%)
2000
9.17
2023
7.99
Key Findings
HbA1c levels declined significantly from 9.17% in 2000 to 7.99% in 2023 (β = −0.037% per year, p < 0.001).
The overall decrease in HbA1c over 23 years was approximately 0.84%.
Improvement in HbA1c levels varied significantly by sex, DKA status at presentation, and age group at diagnosis.
Adolescents aged 12–18 years had the highest HbA1c levels but also showed the steepest rate of improvement (β = −0.084%/yr).
The proportion of patients achieving HbA1c <7.0% increased significantly (OR = 1.029 per year, p = 0.002).
No significant improvement was observed in the youngest age group (0–6 years).
Clinical Implications
The significant decline in HbA1c levels among pediatric patients indicates that advancements in diabetes management are effective. However, the persistent high levels in adolescents highlight the need for targeted interventions in this age group to enhance glycemic control. Clinicians should consider individual patient factors when setting glycemic targets.
Conclusion
Overall, the study demonstrates a positive trend in glycemic control among children and adolescents with T1D, while also identifying specific subgroups that require additional focus to improve outcomes.
Although treatment advances have increased the 5-year relative survival rates across all age groups, including a 15% increase for adolescents and young adults ages 15 to 39 years, it varies widely for...
